Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chinese Firms' Delisting Uncertainty Lifted For Now But Clock Ticking

New US Deal Seen As Just First Step

Executive Summary

A new bilateral agreement between securities regulatory authorities in the US and China is being seen as a welcome first step in addressing issues around US inspections of auditors of US-listed Chinese firms, but implementation will be key. 

You may also be interested in...



BeiGene/Novartis's Tislelizumab Faces US Delay Over China Inspection Challenges

An inability to conduct manufacturing field inspections in China due to strict local COVID-19 policies is cited as the only reason for the delay for the anti-PD-1 drug, for which the timescale for resolution is currently unclear.

SEC Puts US-Listed Chinese Biopharma Firms On Notice To Comply With 2020 Law

Chinese companies publicly traded in the US – including BeiGene, HutchMed and Zai Lab – have three years to switch to accounting firms that can be investigated by the US government, or two years if a pending amendment is adopted.

China's Ongoing 'COVID Zero' Policies To Prompt More Domestic Deals?

China biotechs appear increasingly interested in partnering with domestic counterparts amid signs the Chinese government's restrictive "COVID Zero" policies are likely to stay until well into 2023.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS146933

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel